BioMark Diagnostics Menu Logo
Biomark Diagnostic Solutions

CSE: BUX | OTCQB: BMKDF | FSE: 20B

Non-Invasive Early Detection of Stage I Lung Cancer with 96.8% Sensitivity

Specificity
0 %
Positive Predictive Value
0 %
Negative Predictive Value
0 %

Because

catching it early

matters.

The BioMark Way

Laboratory autosampler with metabolomic profile overlay for BioMark Diagnostics early-stage cancer detection before symptoms.

The Power of
Metabolomics

By analyzing subtle metabolic signatures from a simple blood draw, BioMark enables faster, more accurate identifications of cancer at its most treatable stages. 

Backed by proprietary research, Artificial Intelligence and Machine Learning, and a growing body of clinical data, BioMark is quickly becoming a leader in the early diagnostics market.

  • Plays a major role in early cancer detection by identifying metabolic alterations before tumors are visible on imaging
  • Identifies specific types of cancers through unique metabolite signatures and biomarker patterns
  • Provides rapid, fast, and thorough analysis to support quicker clinical decisions and treatment monitoring
  • Serves as the foundation of life sciences, underpinning BioMark’s innovative approach to diagnostics and personalized medicine
Phytronix Luxon LDTD ion source and mass spectrometry workstation used by BioMark Diagnostics to identify metabolomic biomarkers in liquid biopsy samples.
Identifying Biomarkers in Liquid Biopsy by Using Metabolomics

Biomarkers are proteins, genes, and other molecules. They also affect how cancer can grow, and multiply, in addition to dying within the body.

Clinician in a BioMark Diagnostics laboratory wearing a stethoscope and pink breast-cancer ribbon beside a chemical fume hood used in metabolomic cancer research.
Working with Oncologists

Oncologists are the frontline doctors. Moreover they provide the medical care and treatments for people diagnosed with cancer.

BioMark Diagnostics clinical laboratory workspace where metabolomics data is prepared for artificial intelligence and machine learning cancer analysis.
Leveraging Technology

Artificial Intelligence and Machine Learning are powerful tools. They undoubtedly make the study of cancer easier with faster, more accurate results.

A revolutionary new approach to clinical cancer treatment and commercialization.

Find Out More About What We Do

Learn more about Cancer and BioMark's Innovative Technologies

BioMark and Phytronix: Sub-10-Second Mass Spec for Early Lung Cancer Detection

BioMark and Phytronix pair liquid-biopsy metabolomics with Luxon LDTD mass spec to analyze samples in under 10 seconds, built for faster early lung cancer detection in certified labs.

Inside BioMark Technology: Detecting Cancer Earlier With Metabolomics

Watch how BioMark Diagnostics uses metabolomics and liquid biopsy to find early cancer signals from a simple sample, a less invasive path to detection when treatment can work better.

Why Lung Cancer Is Found Late and How BioMark’s Liquid Biopsy Helps

BioMark’s lung cancer liquid biopsy uses a blood or urine sample to complement imaging and biopsy, aimed at earlier detection, treatment response, and recurrence monitoring.

How Common Is Cancer? Why Early Detection Matters | BioMark

Cancer will affect about 1 in 4 people, and almost everyone knows someone who has faced it. Watch BioMark’s explainer on why earlier detection can change outcomes.

Explore BioMark's Video Channel for More

biomark on youtube

Biomark's Metabolite Breakthroughs

Earlier Detection = Better Outcomes

Metabolomics Liquid Biopsy Platform

Metabolites and genetic biomarkers.

Metabolomics Liquid Biopsy Platform

BioMark focuses on detecting cancer-altered metabolites (small molecules) that provide a strong, amplified signal of early disease changes — offering higher sensitivity than many traditional protein or genetic biomarkers for early-stage cancers like lung, breast, and others.
More

Core SSAT/Amantadine Test

Safe, simple, fast.

Core SSAT/Amantadine Test

A simple, non-invasive test using mass spectrometry. It serves as an accessible front-line screen, with results in hours.
More

Impact On Patient Outcomes

Early cancer detection means better treatment results.

Impact on Patient Outcomes

These tools target earlier detection in high-risk groups, lower costs, fewer invasive procedures, and better survival rates by catching cancer when it’s most treatable — with a growing IP portfolio and collaborations backing commercialization.
Learn More

Multi-Metabolite Panels

Comfortable and painless.

Multi-Metabolite Panels

Targeted panels (plasma/urine) combined with advanced analytics have shown excellent accuracy in large validation studies for early lung cancer, glioblastoma, breast, and other cancers.
More

In-Office / Point-of-Care Testing

Scalable and decentralized

In-Office / Point-of-Care Testing

The workflow is designed for scalability. Prototype/custom kits and standardized protocols are in development, aiming for future doctor’s office or clinic-based equipment that reduces reliance on centralized labs.
MORE
"Early detection of cancer greatly increases the survival rate and biotech companies are showing leadership skills in developing the necessary technology. Biomark has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer."
Melanie Schaffer
Staff Writer - Benzinga

Sign up for the latest BioMark news